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Abstract.  The A-domain is a  ,,o200-amino acid pep- 
tide present within structurally diverse proadhesive 
proteins including  seven integrins.  A  recombinant 
form of the A-domain of/32 integrins  CR3 and LFA-1 
has been recently shown to bind divalent cations and 
to contain binding sites for protein ligands that play 
essential roles in leukocyte trafficking to inflammatory 
sites, phagocytosis and target cell killing.  In this re- 
port we demonstrate that the neutrophil adhesion in- 
hibitor,  NIF produced by the hookworm Ancylostoma 
caninum is a selective CDllb A-domain binding pro- 
tein.  NIF bound directly, specifically and with high 
affinity (Kd of ~1  nM) to recombinant CD1 lb 
A-domain (rllbA).  The binding reaction was charac- 
terized by rapid association and very slow dissocia- 
tion,  and was blocked by an anti-rllbA monoclonal 
antibody. No binding was observed to rCDllaA.  The 
NIF-rllbA interaction required divalent cations, and 
was absent when the mutant rllbA D140GS/AGA (that 
lacks divalent cation binding capacity) was used. The 
NIF binding site in rllbA was mapped to four short 
peptides,  one of which being an iC3b binding 
site. The interaction of NIF with CR3 in intact cells 
followed similar binding kinetics to those with rllbA, 
and occurred with similar affinity in resting and acti- 
vated human neutrophils,  suggesting that the NIF epi- 
tope is activation independent.  Binding of NIF to CR3 
blocked its ability to bind to its ligands iC3b, fibrino- 
gen, and CD54, and inhibited the ability of human 
neutrophils to ingest serum opsonized particles.  NIF 
thus represents the first example of a disintegrin that 
targets the integrin A-domain,  and is likely to be used 
by the hookworm to evade the host's inflammatory re- 
sponse. The unique structure of NIF, which lacks a 
disintegrin  motif, emphasizes basic structural  differ- 
ences in antagonists targeting A + and A- integrins, 
that should be valuable in drug design efforts aimed at 
generating novel therapeutics.  Identification of the re- 
gion in NIF mediating A-domain binding  should also 
be useful in this regard,  and may, as in the case of 
disintegrins,  unravel a new structural  motif with cel- 
lular counterparts mediating important physiologic 
functions. 
M 
ICROORGANISMS have evolved different  strategies 
to subvert the host defense  mechanisms  in favor 
of their own well-being (see references 24, 34 for 
reviews). In many cases, infectivity is established by expres- 
sion of gene products that modulate specific components of 
the host's innate  or adaptive immune responses.  Identifica- 
tion of these products is essential for a detailed understand- 
ing of the complex interactions  between host and pathogens. 
It could also serve as a basis for development of novel drugs 
where such  products are used as selective antagonists  of 
specific components of the hosts' immune response to injury. 
In contrast to bacteria and  viruses,  helminths  are con- 
strained by their slower replication rate. To begin and sustain 
the infection process, it is essential that these parasites  avoid 
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the host's early reactions to injury that is Often mediated by 
circulating  leukocytes and chemoattractants  derived from 
activated endothelial cells or the complement system. In this 
context,  some of the  remarkable  adaptations  include  the 
secretion of an elastase inhibitor by Echinococcus granulosa 
which blocks C5a and PAF-induced chemoattraction  in neu- 
trophils (52), cleavage of PAF by an acetylhydrolase secreted 
by Nippostrongylus brasiliensis (12), and surface expression 
of several antioxidants by Schistosomes (19, 56) to counteract 
the neutrophirs oxidative burst. 
The chemotaxins  that are secreted or expressed at acute 
inflammatory  sites in response to an invading microorgan- 
ism, attract circulating  nentrophils  by activating  a key cell 
surface receptor named complement receptor type 3 (CR3, 
CDllb/CD18, otM/32, Mac-l,  Mol)  (reviewed in reference 
4). Activated CR3 plays an essential  role in immune clear- 
ance  by  facilitating  neutrophil  adhesion  to  endothelium, 
transendothelial  migration,  and  phagocytosis  of  serum- 
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the four members comprising the/32 integrin subfamily that 
share  a  common  /3  subunit  (CD18),  but  have  distinct 
(CDll)  subunits,  the  other  three  members  being  LFA-1 
(CDlla/CD18,  otL/~2, TA-1), p150,95 (CDllc/CD18, t~X/~2, 
Leu-M5), and the recently described macrophage-restricted 
CDlld/CD18 (otTM/32) (17) (reviewed in reference 4). CR3 
binds  in  a  divalent  cation-dependent  manner  to  several 
ligands including iC3b, the major complement opsonin (9, 
10, 60),  fibrinogen (1), and CD54 (ICAM-1)  (21),  through 
non-Arg-Gly-Asp-containing  sequences  (2,  53,  55).  Re- 
cently, the A-(I) domain, a ~200-amino acid segment in the 
extracellular region of the ot subunits of seven integrins has 
been shown to be a metalloprotein, containing a divalent cat- 
ion binding  site(s),  formed by discontinuous hydroxylated 
amino acids (36). Mutations involving the conserved amino 
acids D140GS and D242 within the CD1 lb A-domain impair 
CR3  binding  to  iC3b,  and  mutations  of the  equivalent 
residues  in  CD49b  also  inhibit  binding  of CD49b/CD29 
(t~2/~l) to collagen (29). Recombinant forms of the/~2 inte- 
grin A-domain have been found to bind directly to iC3b (58), 
fibrinogen, and CD54 (46, 61), indicating that this domain 
is a major binding site for physiologic ligands involved in 
leukocyte extravasation and phagocytosis. 
The hookworm Ancylostoma caninum produces a 41-kD 
heavily glycosylated protein called NIF, that inhibits neutro- 
phil spreading and adhesion to endothelial cell monolayers, 
and binds to CR3 (40). In this communication we show that 
CR3 is the sole protein recognized by NIF in neutrophils, and 
demonstrate that the interaction of NIF with CR3 is divalent- 
cation dependent and mediated through the A-domain.  The 
binding site for NIF in the A-domain is comprised of non- 
contiguous peptides, one of which serves as the major iC3b 
binding site (58). NIF is the first example of a selective integ- 
fin A-domain antagonist. Its unique structure, selectivity and 
binding properties should be useful in the design of therapeu- 
tically effective anti-inflammatory agents, and suggest novel 
therapies to treat hookworm infections. 
Materials and Methods 
Reagents and Antibodies 
Restriction and modification enzymes were bought from New England Bio- 
labs (Beverly,  MA),  Boehringer Mannheim Biochemicals (Indianapolis, 
IN) or BRL. The bacterial expression vector pGEX-2T vector was obtained 
from Pharmacia LKB Biotechnology, Inc. (Piscataway,  NJ). The murine 
mAbs directed against human CDIlb  [44  (9),  904  (20),  OKM9  (60)], 
CDlla [TS1/22] and CDI8 [TSI/18] (48), and CDllc [L29]  (32) hawe been 
previously described. The mAb 107 (IgG1) was raised in our laboratory by 
immunizing BALB/c mice with pure recombinant human CD1 lb A-domain. 
This mAb reacts with CDllb but not CDlla  A-domain by ELISA im- 
munoprecipitates CR3 from neutrophil extracts, and binds to neutrophils 
by FACS analysis (unpublished observations). 
Generation and Purification of CDll A-domain 
Recombinant Proteins 
Recombinant proteins encoding wild-type CDlla and CDllb A-domains 
and the non-metal binding CD1 lb A-domain mutant DI4OGS/AGA were ex- 
pressed as GST-fusion proteins in Escherichia coli as described elsewhere 
(36, 58). The fusion proteins were purified by affinity chromatography, used 
as such or cleaved with thrombin to release the rA-domains (54). Recom- 
binant purified NIF (rNIF) 1 was kindly provided by Drs. Matthew Moyle 
1.  Abbreviations  used in  this paper:  EA,  erythrocytes; NEM,  N-ethyl- 
maelamide; ORO,  opsonized oil red O; rNIE recombinant purified NIF; 
RT, room temperature; STI,  soybean trypsin inhibitor. 
and Howard R. Soaie (Corvas International Inc., San Diego, CA). A recom- 
binant soluble form of human CD54 (containing all five Ig domains but 
lacking the intramembranous and cytoplasmic regions) was the kind gift of 
Dr. Jeffrey Ca-eve (Miles Research Center, West Haven, CT) (26). Recom- 
binant protein concentrations were determined using the protein assay kit 
from BioRad Laboratories (Melville, NY),  and analyzed by Coomassie 
staining after electrophoresis on denaturing polyacrylamide gels (31). 
Peptides 
Synthetic peptides were obtained commercially or made at the Howard 
Hughes Biopolymer facility at Massachusetts General Hospital. All pep- 
tides were purified on HPLC, and selective ones were subjected to amino 
acid analysis. All peptides were soluble in water at  1 mg/ml. 
Immobilization of  Recombinant Proteins and Peptides 
Purified rA-domain preparations (1/zg/well), soluble CD54, human fibrino- 
gen (Sigma Chemical Co., St. Louis, MO), gelatin (BioRad Laboratories) 
or  BSA  (Calbiochem-Behring Corp.)  (each  at  10  t~g/well)  or  selected 
A-domain-derived peptides (10 t~g) were added to Immulon-2 96-well mi- 
crotiter plates (Dynatech Labs, Chantilly, VA) overnight. Quanitation of  ad- 
sorbed wild-type and mutant A-domain and synthetic peptides was done 
using the mAb 44 in an ELISA, and the BCA kit (from Pierce Chemical 
Co., Rockford, IL), respectively. Wells were then washed with PBS, pH 7.4, 
without metals, and blocked with 1% BSA for 1 h, washed again in binding 
buffer, and used immediately in the functional assays. 
Preparation of  Complement C3-coated  Erythrocytes 
Sheep erythrocytes were incubated with 1:240 dilution of rabbit anti-sheep 
erythrocyte antiserum (Diamedix Corp. Miami, FL) for 30 min at 37°C to 
generate IgM-coated sheep erythrocytes (EA). EAiC3b was prepared using 
C5-deficient human serum (Sigma Chemical Co.) at 1:10 dilution (60 rain 
at  37°C).  EAiC3b  cells  were  washed and  stored in  isotonic VBSG  ++ 
(veronal-buffered saline, pH =  7.4, containing 0.1% gelatin [VBSG--] and 
1 mM each of CaC12 and MgC12) and to which soybean trypsin inhibitor 
(STI; Worthington Biochemical Co., Freeton, NJ) was added at 1 mg/ml. 
EAiC3b  (at  1.5  x  10  s  cells/nil)  were  labeled  with  5-(and-6)-carboxy 
fluorescein (Molecular Probes, Eugene, OR) at 1:100 dilution of  a 10 mg/mi 
stock for 5 min on ice and washed before use in the binding studies. 
Recombinant CR3 Binding to EAiC3b 
Binding of EAiC3b to recombinant membrane-bound CR3 expressed on 
COS cells was performed as previously described (36). To assess the effect 
of NIF on this interaction, EAiC3b binding was performed in the absence 
and presence of increasing mounts of NIF.  After incubation, cells were 
washed, examined briefly by light microscopy, and then solubiliznd with 1% 
SDS-0.2 N NaOH. Fluorescence was quantified (excitation wavelength, 490 
nm, emission wavelength, 510 nm) on each sample using a  SLM 8000 
fluorometer (SLM Instruments, Urbana, IL) (36). 
Neutrophii Binding to Fibrinogen and CD54 
Human neutrophils were purified as described (14). Binding of neutrophils 
to CD54- or fibrinogen-coated 96-well microtiter plates was performed as 
follows: neutrophils (8  x  106/mi)  were labeled with 5-(and-6)-carboxy 
fluorescein (Molecular Probes) at  1:100 dilution of a  10 mg/ml stock for 
5 min on ice and washed in M199 medium containing an additional 1 mM 
MgC12, 1 mM CaC12 and 0.1% BSA (MB) before use. Fluoresceinated neu- 
trophils (25/zl of 8  x  106/ml) were added to each well containing 25/zl 
of buffer alone or containing 2  x  10  -6 M f-met-leu-phe. The plates were 
centrifuged at room temperature (RT) (800 rpm in a Sorvall RT 6000B) for 
30 s, and incubated for only 5 rain at RT, to avoid cell spreading, a fact 
confirmed by visual inspection of the cells at the end of this incubation 
period. Wells were washed three times with 100/zl of MB each, examined 
by light microscopy, and then solubilized with 1% SDS/0.2N NaOH, and 
fluorescence quantified. To evaluate the effects of mAbs and NIF on bind- 
ing, mAbs (each used at 1:100 dilution of ascites) or NIF (used at 5 #g/ml 
final concentration) were preincubated with fluoresceinated neutrophils for 
15 min at 4°C prior to the binding reaction. 
Phagocytosis Assays 
Phagocytosis of serum opsonized oil red O (ORO) particles was performed 
essentially as described elsewhere (7).  To determine the effect of rNIF or 
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~g/mi) were preincubated with neutrophils for 10 rain at RT prior to addi- 
tion of opsonized ORO. The reactants were p~vanned for 2 min at 37°C 
before mixing. Incubation was then commenced  for 5 rain at 37°C with con- 
tinuous shaking in a water bath. The reaction was stopped by addition of 
1 ml of ice-cold PBS containing 1 mM N-cthyl-maelamide (NEM), fol- 
lowed by two washes. The cell pellet was examined visually for its red color 
(reflecting ingestion of the red oil droplets), and then solubilized with 0.5 
ml of dioxane, and the amount of ORO in the extract quantified by measur- 
ing absorption at 525 nm and converted to milligrams of ORO ingested/l(f 
cells/minute. Specific uptake of ORO was determined by subtracting the 
background (uptake in the presence of 1 mM NEM). 
rNIF Binding, Competition, and Displacement Studies 
100/~g of rNIF were labeled with sulfo-NHS-biotin as described by the 
manufacturer (Pierce Chemical Co.). rNIF binding to resting or stimulated 
human neutrophils (pretreated with 10  -6 M  f-met-leu-phe, for 15 min at 
37°C, and then washed) was measured. Increasing amounts of biotinylated 
rNIF in the absence or presence of 100~fold molar excess of unlabeled rNIF 
were incubated on ice for one hour with 1  x  106 neutrophils in VBSG  ++ 
in a  total volume of 50 ~1.  Ceils were then washed and incubated with 
phycoerythrin-coupled avidin (Sigma Chemical Co.) under similar condi- 
tions, washed again, fixed in 1% paraformaidehyde in PBS, and analyzed 
using FACSean  ® (Becton Dickinson Co., Mountain View, CA). Mean chan- 
nel fluorescence for each sample was then expressed as a function of the 
amount of biotinylated rN1F used. Background binding of phycoerythrin- 
streptavidin alone to neutrophils was subtracted (2.8  fluorescent units). 
Specific binding was obtained by subtracting total binding from that seen 
in the presence of excess unlabeled rNIF, and the values plotted according 
to Scatchard (49). To determine the effect of unlabeled fluid-phase rllbA 
or GST on rNIF binding to neutrophils, each was preincubated at varying 
concentrations with biotinylated rNIF (20 ng/ml, final concentration) for 15 
min on ice before addition of the mixture to neutrophils. The effect of mAbs 
on biotinylated NIF binding to neutrophils was assessed by preincubating 
the uentrophils with 100/~g/ml  of each mAb at 4°C for 15 rain before addi- 
tion of biotinylated NIF (20 ng/ml). The incubation then continued for 1 h, 
followed by processing of cells for FAC$  ® analysis as described above. 
To measure binding of biotinylated rNIF to immobilized rl lbA, increas  - 
ing concentrations of biotinylated rNIF in VBSG  ++, in the absence or pres- 
ence of 100-fold unlabeled rNIE were added to rA-domain-coated 96-well 
microtiter wells, and incubated at RT for 60 rain. Wells were then washed, 
incubated with alkaline phosphatase-coupled avidin, washed again, devel- 
oped  with  substrate,  and  quantified colometrically using  a  microplate 
reader. To evaluate the ability of anti-CD1 lb A-domain mAbs to block bio- 
tinylated NIF  binding to  immobilized rllbA,  coated wells were prein- 
cubated with the mAbs (each at 100 #g/ml or 1:100 dilution of ascites) for 
15  rain at RT. Biotinylated NIF (50 ng/ml final concentration) was then 
added, and incubation continued for an additional hour. To assess the ability 
of fluid-phase rllbA or GST to block biotinylated NIF binding to immobi- 
lized rllbA, each was preincubated at 7 #g/ml with biotinylated NIF (50 
ng/ml final concentration) in a total volume of 50 pl for 15 min at RT, fol- 
lowed by incubation of this mixture with the rl lbA-coated wells for an addi- 
tional hour.  In experiments where the effects of divalent cations on bio- 
tinylated rNIF binding to immobilized rCDllb A-domain were measured, 
VBSG-- buffer was used as such, containing 1 mM of Ca  2+, Mg  2+, Mn  2+, 
EDTA, EGTA, EGTA plus 1 mM MgCI2,  or 1 mM MnC12. In these ex- 
periments, BSA-blocked A-domain-containing wells were first washed with 
buffer containing 10 mM EDTA (to remove protein-bound cations), and 
then washed with the respective binding buffer. The effect of temperature 
was evaluated in the presence of the standard divalent cation mixture at 37 °  , 
22 °, and at 4°C with saturating amounts of biotinylated rNIF (200 ng/ml). 
The kinetics of  rNIF-neutrophil or rNIF-A-domain interactions were de- 
termined as described (33). Neutrophils or immobilized rA-domains were 
each incubated with half-saturating concentrations of biotinylated rNIF (20 
ng/ml and 40 ng/ml for neutrophils and immobilized rA-domain, respec- 
tively), in the absence or presence of 100-fold  molar excess of unlabeled 
rNIF at 4°C (with neutrophils) or at RT (with immobilized rA-domain). The 
specific binding of biotinylated rNIF was determined at various times as de- 
scribed above, and plotted versus time. The time required to reach equilib- 
rium  was  one  hour.  The  value  for tu2  of association was  determined 
graphically from the association plot. To determine dissociation rates, neu- 
trophils or immobilized A-domain was incubated for 1 h with the respective 
half-saturating concentrations of biotinylated rNIF mentioned above, in the 
absence or presence of 100-fold molar excess of unlabeled rNIF, at 4°C (for 
neutrophils) or at RT (for immobilized A domain). Afterwards, neutrophils 
were washed twice in VBSG  ++ and incubated in 4 ml of this buffer on ice 
with shaking. At various time points, aliquots were removed, centrifuged 
and the amount of specifically bound rNIF measured. For immobilized 
rllbA, wells were washed twice and incubated with 300 #1 of VBSG  ++ per 
well a1 RT with shaking. At various time points, the buffer was removed and 
specific binding measured. The dissociation rates in each case were deter- 
mined by plotting  -ln(BIB~q)  versus time, where B  and B~ represent, 
respectively, the fraction of rNIF bound to cells (or to immobilized rl lbA) 
at time t, and at equilibrium. The value for h/2 of dissociation was calcu- 
lated according to the formula tl/2  =  ln2/Kon (33). 
Surface Biotinylation, Immunoprecipitation, 
and Western Blotting 
Surface biotinylation of purified human neutrophils was performed on ice 
by incubating the cells (3  x  107/ml in PBS) with 0.1 mg/ral final concen- 
tration of snlfo-NHS-biotin  (Pierce Chemical Co.) for 30 min at 4°C. After- 
wards, ceils were washed twice in PBS, quenched for 15 rain in RPMI on 
ice and washed once again in PBS. The NP-40-soluble fraction from unla- 
beled or biotin-labeled cells was used to immunoprecipitate/32 integrins 
with the anti-CDlla, b, c-specific mAbs (TS1/22,  44, L29, respectively). 
Immunoprecipitates were electrophoresed on gradient 4-16%  polyacryl- 
amide gels in Laemmli buffer (31), electrobloued onto Immobilon-P mem- 
branes, and blocked with BSA. Membranes containing immunoprecipitates 
from surface-biotinylated cells were then probed with HRP-coupled avidin 
(Sigma Chemical Co.), while those with immunoprecipitates from unla- 
beled cells were first probed with biotinylated rNIF (at 1/~g/ml), washed 
then re-probed with HRP-coupled avidin (Sigma Chemical Co.).  Mem- 
branes were developed using the enhanced chemiluminescence  system from 
Amersham Corp.  (Arlington Heights, IL). 
Results 
Binding Characteristics of rNIF 
to Human Neutrophils 
The optimal parameters of neutrophil binding to biotinylated 
rNIF were determined. Measurement of the time course of 
association of biotinylated NIF with neutrophils at 4°C (to 
avoid endocytosis) revealed a rapid uptake,  with maximum 
levels  achieved  within 60  rain,  and  with a  tm at  15  min 
(Fig. 1 A), as previously shown (40), and was completely in- 
hibited in the presence of 100-fold molar excess of unlabeled 
NIF at each time point. 
Upon washing and dilution of cells preincuhated  for 1 h 
at  4°C  with  biotinylated  rNIF,  the  cell-associated  rNIF 
slowly dissociated with a  t~12 of ,x,7.6 h  (Fig.  1 A,  inset). 
Thus, the association of rNIF with neutrophils  is reversible 
and characterized  by rapid binding and very slow dissocia- 
tion.  The slow dissociation rate permitted the use of bio- 
tinylated rNIF under the conditions described to evaluate its 
interaction with whole cells and with protein fragments.  The 
slow dissociation observed here, together with the fact that 
Moyle et al. performed their binding studies to f-met-leu- 
phe-activated  neutrophils at RT where endocytosis of CR3 
can take place (16, 45), may account for the previous sugges- 
tion that binding of NIF to neutrophils  is irreversible (40). 
Incubation  of increasing  concentrations  of biotinylated 
rNIF with resting or activated  neutrophils  at 4°C, revealed 
a predominantly saturable  component (Fig.  1 B),  with the 
non-saturable  (nonspecific) fraction (obtained in the pres- 
ence of 100-fold molar excess of unlabeled rNIF) accounting 
for less than  10% of the total binding. A Scatchard  plot of 
the binding data (Fig. 1 B, insets) indicated a linear relation- 
ship in both resting and activated cells. Both cell types bound 
NIF with approximately similar affinities (K~ ranging  from 
0.35 to 1.3 nM), suggesting that the 12-fold increase in NIF 
binding to activated vs resting cells is primarily due to an in- 
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Figure 1. (A) Time course of the specific association of biotinylated 
NIF (20 ng/ml) with neutrophils. Association was maximal by 1 h 
at 4°C, with a tu2 of association of 15 min. The mean +  SE of hi2 
from this and two additional experiments was 15 5:5 min. (Inset) 
Time course of  the release at 4°C of  biotinylated rNIF from neutro- 
phil  s following one hour of  binding, removal of  the unassociated la- 
bel,  and a  100-fold dilution in buffer alone.  The Kon for rNIF 
binding to neutrophils (given by the slope of the curve) was = 2.5 
10  -5 s  -~, with a dissociation tl/2 of= 460 rain. (B) Specific binding 
of increasing concentrations of  biotinylated rNIF to purified resting 
and f-met-leu-phe activated human neutrophils. Specific binding 
was obtained by subtracting non-specific binding (in the presence 
of 100-fold molar excess of unlabeled rNIF) from total binding (in 
the absence of unlabeled NIF). (Inset) Specific binding to resting 
and  activated neutrophils plotted  according  to  Scatchard.  The 
results shown are from one experiment, with similar results ob- 
tained in two others. 
crease in the number of NIF binding sites induced by cell ac- 
tivation (4). 
Effects of rNIF on Neutrophil Ligand Binding 
and Phagocytosis 
The effects of rNIF on CR3-mediated neutrophil binding to 
the physiologic ligands  complement iC3b,  fibrinogen and 
CD54 were measured, rNIF inhibited binding of EAiC3b to 
recombinant human CR3 (expressed in COS cells) in a dose- 
dependent  manner  with  complete  inhibition  achieved  at 
3/~g/ml (IC50 of "~5 nM) (Fig. 2 A).  rNIF also abolished 
iC3b-dependent phagocytosis of sernm-opsonized oil  red 
O particles by human neutrophils (Fig. 2 A, inset). 
Binding of f-met-leu-phe-activated  fluoresceinated neutro- 
phils to microtiter wells coated with human fibdnogen or 
soluble CD54 was also inhibited significantly in the presence 
of NIF (5 pg/ml) (Fig. 2, B and C). Inhibition of neutrophil 
binding to fibrinogen was incomplete even at high NIF con- 
centrations (50 pg/ml) (Fig. 2 B). CD54 binds to both LFA-1 
and CR3 (21, 35). Complete inhibition of neutrophil-CD54 
interactions therefore requires the simultaneous use of  mAbs 
directed against both antigens (Fig. 2 C). Although NIF did 
not inhibit neutrophil binding to CD54 when used alone, it 
abolished this binding when combined with an anti-CD1 la 
mAb (Fig. 2  C). 
CR3 is the Receptor for NIF in Neutrophils 
The structural basis for the ability of rNIF to inhibit CR3- 
mediated functions in neutrophils was explored. Although a 
previous study showed that NIF binds to neutrophil CR3, it 
did not evaluate the subunit binding specificity, and did not 
establish whether CR3 is the only receptor for NIF on the 
neutrophil surface. To address the first question, we probed 
western  blots  of heterodimeric CR3  immunoprecipitated 
from unlabeled neutrophils with biotinylated rNIF, and com- 
pared the pattern with biotinylated CR3 (generated by sur- 
face biotinylation of neutrophils). This analysis showed that 
rNIF binds to the CDllb but not the CD18 subunit of the 
CR3 heterodimer (Fig. 3, A and B). rNIF did not bind to the 
other two B2 integrins CD1 la or CD1 lc expressed on neutro- 
phils (Fig. 3, A and B). 
To determine if CR3 is the only receptor on the neutrophil 
surface that binds to NIF, we evaluated several anti-CD1 lb 
mAbs known to inhibit CR3 functions for their ability to 
block the  binding  of biotinylated NIF to neutrophils.  As 
shown in Fig.  3 C,  the mAb 107 inhibited NIF binding to 
neutrophils completely. Two other anti-CD1 lb mAbs 44 and 
904 and the anti-CDlla mAb (TS1/22)  had no inhibitory 
effects. 
rNIF Binds to the CDllb A-domain 
Recent evidence has shown that rl lbA binds directly to iC3b 
(58), fibrinogen and CD54 (61). The fact that NIF inhibited 
neutrophil binding to these ligands  (Fig.  3) and that NIF 
binding to neutrophils was blocked by a mAb raised against 
r 1  lbA (Fig. 3 C) led us to examine the ability of NIF to bind 
directly to this domain, rl lbA and rl laA were expressed as 
GST fusion proteins, used as such or after thrombin cleavage 
(36,  58).  Each  recombinant protein  reacted  with  several 
blocking monoclonal antibodies (44, 904, OKM9 and 107 
in the case of the rl lbA, and TS1/22 and L1 in the case of 
the rllaA (58; and data not shown). 
Biotinylated rNIF bound directly and specifically to im- 
mobilized rllbA (Fig. 4, A and B). Binding of rNIF to this 
domain was characterized by a rapid on rate (Fig. 4 A), and 
a slow off rate (Fig. 4 A, inset), that were almost identical 
to those characterizing NIF binding to whole neutrophils 
(Fig.  1 A).  NIF  binding  to  immobilized rA-domaln  was 
specific and  saturable.  Scatchard analysis  of this binding 
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Figure  2. (A) rNIF-induced inhibition of binding of EAiC3b to COS 
cells expressing rCR3. Values represent the mean +  SD of three 
independent experiments each carried out in triplicate. Dotted line 
represents background binding of EA to rCR3. (Inset) Histograms 
(mean  +  SD, n  =  four determinations)  showing the  inhibitory 
effects of rNIF or an anti-CD1 lb rnAb (44) on ingestion of serum- 
opsonized paraffin oil red O (ORO) by human neutrophils. Inges- 
tion rate in buffer alone was 0.44  +  0.12 mg ORO/105 cells/min, 
mean 5: SD, n = 4 determinations).  (B) Histograms (mean +  SD 
of three  independent  experiments  each carried  out in triplicate) 
yielded an apparent Ks of •1  nM (Fig. 4 B, inset), similar 
to that obtained when the neutrophil-bound native CR3 was 
used (Fig.  1 B).  In western blots, biotinylated NIF bound 
directly to rllbA but not to rllaA (Fig. 4  C), and binding 
to rllbA was inhibited completely by the mAb 107, and par- 
tially by OKM9, but not by 44, 904 or TS1/22  (Fig. 4 D), 
indicating the specificity of rllbA-NIF interactions. 
NIF Binding to Recombinant 11b A-domain 
Is Metal Dependent 
The CD1 lb A-domain has been shown to contain a discon- 
tinuous divalent cation binding site(s) that is essential for the 
binding of CR3 to iC3b (36, 58). To determine if NIF inter- 
action with rl lbA is cation dependent, we examined the role 
of divalent cations on this interaction. As can be seen in Fig. 
5 A, binding of NIF to immobilized rl lbA required divalent 
cations, as it was blocked in the presence of EDTA. EDTA 
was also able to completely reverse rllbA-NIF interaction 
even when added 1 h after the complex is formed (Fig. 5 A). 
NIF bound to rllbA in VBSG-- buffer under these condi- 
tions, and binding was not significantly affected by Chelex 
treatment of VBSG-- (not shown) or by addition of Ca  2+, 
Mg  2÷, or Mn  2+ each at 1 mM (Fig. 5 A). Addition of EGTA 
at 1 mM to the VBSG-- buffer reduced NIF binding only 
marginally, indicating that binding can occur in the absence 
of Ca  2+. As the other cations (e.g., Mg  2÷, Mn  2+) cannot be 
selectively chelated, we cannot exclude that binding of NIF 
to rllbA can occur in presence of Ca  2+ alone. Since binding 
is abolished by EDTA, trace amounts of other divalent cat- 
ions (derived from the buffer salts, gelatin, glucose, or BSA) 
are essential. The divalent cations appear to be required at 
least at the level of the A-domain,  since the mutant rl lbA 
(D140GS/AGA) that lacks the metal binding site(s) did not 
bind NIF even in the presence of 1 mM each of Ca  2+ and 
Mg  2÷ (Fig.  5 A). Binding of NIF to the A-domain was not 
affected by temperature (Fig. 5 A) as in whole cells. Fluid- 
phase rl lbA, but not its fusion partner GST, abolished bio- 
tinylated rNIF binding to human neutrophils (Fig. 5, B and 
C) or to immobilized rllbA (Fig. 4 D; and data not shown) 
in a dose-dependent manner, with half-maximal inhibition 
seen at ,x,1 nM in each case, reflecting the lack of significant 
structural  differences  between  the  adsorbed  and  soluble 
forms of rl lbA. 
showing the effect of NIF or the anti-CDl8 mAb (TS1/18) on bind- 
ing of activated neutrophils to immobilized fibrinogen. Binding in 
the presence of buffer alone is expressed as 100%. The ascites con- 
trol NS1 had no effect on neutrophil binding to fibrinogen. (Inset) 
Histograms showing the binding of unstimulated (hatched histo- 
grams) or f-met-leu-phe-treated neutrophils (black histograms) to 
immobilized fibrinogen and gelatin.  (C) Effect of the  [nAbs 44 
(anti-CDllb), TS1/22 (anti-CDlla),  the  negative control  ascites 
NS1 and NIF, on activated neutrophil binding to immobilized solu- 
ble CD54. Each histogram represents mean + SD of  three indepen- 
dent experiments each in triplicate. (Inset) Comparison of the bind- 
ing  of  resting  (hatched histograms)  and  f-met-leu-phe-treated 
neutrophils (black histograms) to CD54 and to BSA. Each histo- 
gram represents the mean +  SD of three independent experiments 
each carried  out in triplicate. 
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Figure 3.  (A) ~2 integrins expressed on neutmphils, l~dioauto- 
graph of a Western blot showing the biotinylated B2 integrin ~ 
subunits (CDlh (hne b), CDllb (lane c), CDllc (lane a), and the 
common B subunit CD18 (lanes a-c)  immunoprecipitated from 
surface-biotinylated neutmphils.  Lane  d  is  a  negative control 
representing immunoprecipitates from  biotmylated neutrophils 
using the nonreactive NS-1 ascites. (B) l~dioautograph of a West- 
ern blot run in parallel to the one in A, in which unlabeled/~2 inte- 
grins were immunoprecipitated  from neutrophil lysate and probed 
with biotinylated rNIE The latter bound to CDllb (lane c) but not 
CDlla, CDllc, or the common CD18 subunit (arrows). Binding 
was done in the presence of the divalent cations CaC12 plus MgC12 
each at 1 mM. (C) FACS  ® analysis showing that binding of bi- 
otinylated  rNIF to resting human neutrophils in the presence of the 
control  anti-CDlla  rnAb TS1/22 [122], and  the  anti-CDllb 
A-domain mAbs 44, 904,  and 107. 107 reduced staining to the 
background levels obtained by omission of  biotinylated  rNIF (trac- 
ing not shown). 
Mapping of the rNIF Binding Site 
in the CDllb A-domain 
To identify  the site in rl lbA involved in NIF binding, 11 over- 
lapping peptides spanning the A-domain were synthesized 
and tested for their ability to inhibit NIF binding to immobi- 
lized r11bA. We found that the two contiguous peptides (A6 
and A7) inhibited binding of rNIF to rCD11b A-domain dra- 
matically (Fig. 6 B). A scrambled form of A7 had no such 
effect (Fig. 6 B). Two additional peptides (A1 and A12), lo- 
cated at the beginning and end of the domain had moderate 
and weak inhibitory effects respectively (Fig. 6 B). Dose- 
response curves (Fig. 6 C) revealed that while combining A6 
and A7 each at 161 #g/ml (80-115  #M) achieved complete 
inhibition of biotinylated NIF binding to r11bA, addition of 
A1 (but not A12) produced a shift in the binding curve to the 
left suggesting that A1 within the recombinant A-domain also 
contribute to NIF-rllbA interaction (Fig. 6 C). Some pep- 
tides (A7, A7M, A3, All) adsorbed well to microtiter plates, 
allowing an assessment of the direct binding of rNIF to these 
peptides. As can be seen in Fig. 6 C (inset) biotinylated rNIF 
bound to immobilized A7 peptide but not to A3 and All. 
Binding of NIF to A7 was not affected when the aspartate 
residue at position 242  (involved  in metal coordination in 
rllbA and CR3) is replaced with alanine (Fig.  6 C, inset). 
Direct binding of rNIF to A6, A1, A12 could not be tested 
because these peptides did not adsorb adequately to plastic 
wells. 
Discussion 
The  major  finding in  this  report  is  that the  hookworm- 
derived NIF  is  a  specific  CR3  antagonist,  that binds  to 
neutrophils through the CD1 lb A-domain and inhibits their 
ability to recognize several CR3 ligands and to mediate pha- 
gocytosis. The binding of NIF to the CDllb A-domain is se- 
lective, of high affinity and divalent cation-dependent. The 
NIF binding site in rllbA partially overlaps that of human 
iC3b, the major complement C3 opsonin. 
Evidence supporting that CR3 is the sole receptor on the 
neutrophil surface for NIF is based on four types of experi- 
ments. First, binding of biotinylated NIF to intact ceils was 
completely blocked by an anti-CR3 mAb (Fig. 3 C). Second, 
probing western blots of detergent extracts from normal or 
~2 integrin-deficient (3) neutrophils with biotinylated NIF 
revealed a single specific band, that of CD11b, in normal cell 
lysates, that was lacking in the genetically deficient cells (not 
shown). Third, of  the three/~2 integrins immunoprecipitated 
from normal neutrophils, only the CD11b subunit reacted 
with biotinylated NIF in Western blots (Fig. 3, A and B). 
NIF bound to neutrophil CR3 with high affinity (riM range) 
and inhibited the binding of neutrophils to the CR3 ligands 
iC3b, fibrinogen and CD54 (Figs.  1 and 2). Fourth, soluble 
r11bA completely blocked the binding of biotinylated NIF to 
neutrophils.  These  findings indicate that NIF  is  a  highly 
selective CR3 antagonist. 
Previous studies have identified several naturally occur- 
ring proteins, so-called disintegrins, that bind to other inte- 
grins with high affinity and block integrin-mediated adhe- 
sion (reviewed in reference 43). Disintegrins isolated from 
leeches and snake venoms inhibit adhesion-dependent func- 
tions  such  as  platelet  aggregation  when  present  in  low 
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nanomolar concentrations. The majority of disintegrins con- 
tain the tripeptide Arg-Gly-Asp and have so far been shown 
to bind to integrins lacking the A-domain (for example some 
members of the ~,/~3, and B5 integrins).  Disintegrins inter- 
act with their respective receptors through a disintegrin do- 
main,  a  ~,,60-amino  acid  motif  with  a  characteristic 
cysteine-rich profile (25). NIF neither contains an Arg-Gly- 
Asp sequence,  nor the disintegrin  motif (40).  The unique 
structure  of NIF  probably  reflects  different  structural  re- 
quirements  for antagonists  targeting  A-domain-containing 
integrins. It is interesting to note that the physiologic ligands 
of CR3 such as iC3b, fibrinogen, and CD54 do not contain 
or do not require an Arg-Gly-Asp sequence (2, 53, 55). The 
disintegrin motif has been recently found in several cellular 
proteins expressed on sperm cells (13), epididimal epithelial 
cells (42),  monocytes (39),  and appears to play important 
roles in fertilization  and tumor suppression (22).  NIF may 
similarly  contain  a  novel motif with  cellular  counterparts 
functioning perhaps in regulating important physiologic in- 
teractions. Identification of the active site in NIF involved in 
integrin binding  should be very useful in this regard. 
The binding site of NIF in CR3 is the A-domain. This con- 
clusion is based on the following observations.  First,  NIT 
bound to rllbA directly,  specifically and with kinetics and 
affinity very similar to that in whole neutrophils  (compare 
Fig.  1 and 4, A and B). Second, binding of NIF to immobi- 
lized rl lbA was blocked by the anti-CDllb  A-domain mAb 
107 or with excess unlabeled fluid-phase rllbA (Fig. 4  C). 
Third,  fluid-phase rl lbA completely blocked the binding of 
biotinylated N1F to intact neutrophils (Fig. 5, B and C). The 
A-domain  was  first identified  in  von Willebrand  factor,  a 
multimeric protein that plays essential roles in platelet adhe- 
sion and hemostasis (59). Cloning studies later showed that 
this domain is also present in single or multiple copies in sev- 
eral otherwise structurally unrelated proteins including ma- 
trix proteins (cartilage matrix protein, collagen VI, XH, and 
XIV), plasma proteins (complement factors C2 and B, inter- 
a-trypsin inhibitor), and cell surface proteins (CD1 la,b,c,d/ 
CD18, a131, ot2/31, MEL/T/,  malarial  TRAP and hypothet- 
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Figure 4.  (A) Time course of the specific association at RT of bi- 
otinylated rNIF with immobilized  CDllb A-domain. Specific bind- 
ing was obtained as described in the legend to Fig. 1 B. Each time 
point represents mean +  SD of triplicate determinations. Similar 
results were observed in a second experiment. (Inset) Time course 
of dissociation of bound rNIF from immobilized  CD1 lb A-domain. 
See Materials and Methods for experimental protocol and calcula- 
tions. (B) Specific binding  (total binding  minus binding in the pres- 
ence of 100-fold molar excess of unlabeled NIF) of biotinylated 
rNIF to immobilized r11bA.  (Inset) Scatchard plot of the specific 
binding data shown in B. (C) Coomassie stain (lanes I  and 2) and 
radioautograph of a Western blot (lanes 3 and 4) showing the bind- 
ing of biotinylated rNIF to rCDllb- (lanes 1  and 3), but not to 
rCDlla (lanes 2  and 4) A-domain fusion protein. Lanes 1 and 2 
show that equivalent amounts of both fusion proteins were used. 
Binding was  done in the presence of the divalent cations CaC12 
plus MgCI2 each at 1 mM. (D) Effect of mAbs or peptides on the 
binding of biotinylated NIF to immobilized rl lbA. Each histogram 
represents the mean :t: SD of three independent experiments each 
carried in triplicate. The mAbs used were 44, 904,  107, OKM9 
(against CDllb), and TS1/22  (anti-CDlla, as a negative control). 
Fluid-phase rl lbA and GST were used at 7 #g/ml. Unlabeled NIF 
was used at  100-fold molar excess. 
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ical protein 337.6 of Caenorhabditus elegans) (reviewed in 
references 18,  47).  The A-domain thus appears  to be the 
product of a primordial gene that served some primitive rec- 
ognition function, and later incorporated into several pro- 
teins to mediate specialized adhesive functions. The studies 
reported here are  the  first to  identify a  naturally occur- 
ring integrin antagonist directed exclusively to the integrin 
CD1 lb A-domain. It has recently been shown that Echo virus 
1, a picorna-virus, uses the A-domain-containing integrin 
CD49b/CD29 (c~2/~1) for cell attachment (11). Given the fact 
that several ligand binding activities in (~2 integrins map to 
their A-domains, it will be of interest to determine if Echo 
virus 1 also uses the CD49b A-domain to infect the host. 
The interaction of NIF with the rl lbA (Fig. 5 A) as well 
as with whole cells (data not shown) requires divalent cat- 
ions. Binding in either case did not occur in the presence of 
EDTA, and was reversed even when EDTA was added after 
the receptor-ligand complexes have formed (Fig. 5 A). A re- 
cent study has shown that the CD1 lb A-domain is a metal- 
loprotein containing a divalent cation binding site(s) formed 
by two noncontiguous segments of the protein (36).  Point 
mutations (D140GS/AGA and D242A) affecting two sepa- 
rate regions in rl lbA blocked 54Mn binding to this protein 
and interfered with iC3b binding to mutant CR3 (36, 58). As 
in the case of iC3b, biotinylated NIF did not bind to mutant 
D140GS/AGA rllbA (Fig.  5 A), indicating that binding of 
these two ligands requires an intact metal binding site in the 
A-domain. While the divalent cation requirements for fibrin- 
ogen and CD54 binding to the A-domain remain to be deter- 
mined (46,  61), binding of several mAbs (such as 44, 904, 
and OKM9) to rllbA is unaffected by removal of cations 
(data not shown). The fact that divalent cations are required 
for the binding of NIF as well as iC3b to rllbA, and that this 
requirement disappears when synthetic peptides are used, 
suggest that cations play an indirect role in ligand binding, 
perhaps stabilizing a specific permissive conformation. So- 
lution of the three dimensional structure of the A-domain 
will be important in evaluating this possibility. 
CR3 exists in multiple cellular compartments in phago- 
cytic cells.  These include the specific (8,  57) and tertiary 
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Figure 5.  (A) Histograms (mean +  SD) from three experiments 
each done in triplicate, showing the effects of divalent cations and 
temperature on binding of biotinylated rNIF to immobilized rl lbA 
wild-type or mutant D140GS/AGA. In each case binding in the 
presence of 100-fold excess of unlabeled NIF is shown as white 
histograms.  The  dotted  histograms  show binding  in  VBSG-- 
(buffer)  alone,  or  containing  1  mM  Ca  2+  plus  1 mM  Mg  2÷ 
(Mg2+/Ca2+),  1 mM Ca  2+, Mg  2+, or Mn  2+,  1 mM EDTA, 1 mM 
EGTA, 1 mM Mg  2+ and 1 mM EGTA, or 1 mM Mn  2+ and I mM 
EGTA. Crossed histograms show that preformed rNIF- immobi- 
lized rl lbA complexes are maintained as long as cations are present 
but rapidly dissociate if EDTA is added. Hatched histogram repre- 
sent biotinylated NIF binding to immobilized mutant  D140GS/ 
AGA rl lbA (in Mg2+/Ca  2+ buffer). The black histograms represent 
binding of  biotinylated NIF to rl lbA at different temperatures in the 
presence of Mg2+/Ca2+-containing buffer. (B) Dose-dependent in- 
hibition of biotinylated NIF binding to neutrophils by increasing 
amounts of fluid-phase rl lbA. Labeled NIF was used at a concen- 
tration that produced 50 % binding to resting neutrophils. Similar 
results were obtained in a second experiment. (C) FACS  ®  analysis 
showing the  binding of biotinylated  rNIF  (used at  the  half- 
saturation concentration) to resting human  neutrophils (Biotin. 
rNIF) and its complete inhibition by fluid-phase rllbA (150 #g/ml) 
(dotted lines).  No inhibition is observed with GST (slashed line). 
The negative control was  obtained  by omission of biotinylated 
rNIE 
The Journal of Cell Biology, Volume  127, 1994  2088 A 
PeDt  ide  ~  Besiche No. 
Al :  C[~EDSDIAF  ~IIP  (128-147) 
A2  :  IIPHDFR~4<  [FVS~L  (145-164) 
A3:  EQI/q<SKT~ SI/vQYSE~  (162-181) 
A4  :  ~  ~PRSL  (179-198) 
A5:  RSLVKPITQL ~ATGI  (196-215) 
A6:  TGIRKWREL FNI~  (213-232) 
A7:  NAFKILVVIT [X~K  (232-245) 
B-2:  DEEK~/]PLG YEDVIPEA[R  (242-261) 
All  :  D~YVI  G%UDAFR  (260-276) 
}3-5:  FF.SEKS}{)KL  NTIASKPPR] HV  (275-296) 
AI2:  ~  IA'T  IQhDIRE  (295-314) 
ATM: 
Scram. A7: 
NAFKILVVIT a6EK 
TVDIZFGIKN IEAV 
B 
~--~ 300' 
.~.  200' 
~. 
lOO. 
'*'E 
A1  A2  A3  A4  A5  A6  A7  B-2  All B-5A12Sc.A7 
C  120hA7+A4+A 3 
,9 ~  1  o] 
100  4+A12  ~ ~  08 
1t ~  J  ~  \+A4  "~ ~  ' 
Z'~ 
~,....~  A3  A1 1 GiST 
•  .~E  40  O  O 
20 
0  i 
0  100  200 
Amount of each peptide added (I.tg/ml) 
Figure 6. (A) Sequence of the synthetic peptides used in this study. 
The name and position of the overlapping peptides synthesized 
based on the amino acid sequence of CD1 lb (6) is shown. Scram. 
A7 is scrambled sequence of A7. A7M is a mutant form of  A7 where 
the Asp. residue is replaced synthetically  with Ala. (B) Histograms 
(mean + SD, n = 3, each in triplicate) showing  the effects  of  CDllb 
A-domain-derived synthetic peptides (at 140 tiM) on binding of 
biotinylated rNIF  (2.5 nM) to immobilized rllbA.  (C)  Dose- 
granules  (gelatinase granules)  (28)  in neutrophils, perox- 
idase-negative granules in monocytes (37),  and secretory 
vesicles in both cell types (30, 50). In unstimulated neutro- 
phils,  •5  % of CR3 is present on the plasma membrane, 
~75% is in the specific and tertiary granules, and ~20% is 
in secretory vesicles which also contain cytochrome b55s, 
CR1,  f-met-leu-phe  receptors,  alkaline  phosphatase  and 
plasma proteins such as albumin (51). Activation of phago- 
cytic cells with several agonists leads to the rapid transloca- 
tion of CR3 from these pools to the cell surface, and an in- 
crease in its numbers by up to 10-fold (8). In addition, CR3 
is also internalized in macrophages (15) and in transfected 
COS cell lines (45), and actively recycles in human neutro- 
phils (16). The rapid redistribution of CR3 may be important 
in replenishment of receptors lost (perhaps through endocy- 
tosis) from the leading front to the cell's uropod during neu- 
trophil migration (23).  Our findings that monomeric fluid- 
phase rNIF binds to both the inactive and active forms of CR3 
with equal and high affinity, and in an EDTA-reversible man- 
ner are unique. These properties could be invaluable in prob- 
ing the dynamics of CR3 recycling, in determining if some 
of the contents of secretory vesicles accumulate through 
a CR3-dependent endocytic pathway, similar to the one de- 
scribed in platelets (27),  and in evaluating the competence 
of the A-domain metal binding state in internalized CR3. 
The binding site for NIF in the CD1 lb A-domain is broad, 
comprised primarily of two centrally located overlapping 
peptides A6 and A7, with additional contribution by two pep- 
tides located at the beginning (A1) and end (A12) of the do- 
main. These data predict that Aft, A7, A1 and A12 are spa- 
tially close in the three-dimensional structure of the domain, 
perhaps lying on one side of the protein. A7 has previously 
been found to bind to iC3b, suggesting that the NIF binding 
site overlaps with that of iC3b. This may explain the ability 
of  NIF to completely block the binding of  this ligand to rCR3 
(Fig. 2 A) as well as to rl lbA (data not shown). The fact that 
NIF inhibits CD54 binding to neutrophil CR3 completely 
(Fig.  2  C) also suggests  common or overlapping binding 
sites for iC3b, CD54, and NIE Inhibition of CR3-fibrinogen 
binding by NIF was partial (Fig. 2 B). This finding could 
reflect differences in the binding sites for iC3b, CD54, and 
fibrinogen in rl lbA. It remains possible however that fibrino- 
gen may bind to CR3 at more than one site, or through an 
additional receptor. Detailed studies evaluating the kinetics, 
metal requirements and conditions under which the binding 
of CD54 and fibrinogen to rllbA takes place, and mapping 
and mutagenesis studies to define the binding sites will be 
required to evaluate these possibilities. The broad interactive 
region between rllbA and NIF may account for the high 
selectivity of this protein to CDllb but not CDllc (which 
binds iC3b) (41): although the A7 region is highly conserved 
in both receptors, the regions encoding A1, Aft, and A12 are 
less conserved. 
response curves (mean + SE, three experiments each in triplicate) 
showing  the effects  of combinations  of A6, A7, A1, and A12 on bio- 
tinylated NIF binding to immobilized rllbA.  (Inset) Histograms 
(mean + SD, n = 3, each in triplicate) showing  the direct binding 
of biotinylated rNIF (400 riM) to the immobilized peptides A7, 
A7M. Binding to rl lbA is shown for comparison. Controls con- 
sisted of GST, and the A-domain-derived peptides A3 and A11. 
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cause loss of ,07  million liters of blood daily  worldwide 
(44). The larvae penetrate skin, migrate through the lungs, 
are coughed up, and then swallowed. In the intestine, they 
mature  into adult  worms,  and  persist  within the host  for 
many years. The major clinical manifestations of hookworm 
disease are due to chronic gastrointestinal  blood loss. Gross 
and microscopic examination of the bowel itself reveals con- 
spicuously little damage (44). The intestinal  wall is usually 
thickened by edema, principally localized to the submucosa, 
with minimal infiltration  of the infested region by neutro- 
phils (38), suggesting that hookworms are able to evade the 
host's immune defenses. By locally producing a factor that 
blocks CR3-mediated functions in neutrophils, hookworms 
may be able to prevent neutrophil extravasation into infected 
regions, and the destruction of the parasites through  their 
phagocytic and killing abilities. Because rl lbA inhibits  NIF 
binding to leukocytes in the low nM range whereas its inhibi- 
tion of iC3b binding to the same cells requires micromolar 
concentrations (58), it is conceivable that the rllbA may be 
useful as such or in a modified form in treating  hookworm 
infections, without producing generalized immunosuppres- 
sion.  In addition, the present study highlights the integrin 
A-domain as a specific target in development of novel anti- 
inflammation therapeutics,  that could be very beneficial in 
mitigating  phagocyte and complement-induced tissue injury 
during  immune and  inflammatory  disorders  (3),  a lesson 
long learned by the hookworm. 
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